(Q33490474)

27 July 2017

Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study (English)

1 reference

27 July 2017

C F Pollera

1

1 reference

27 July 2017

A Ceribelli

series ordinal

2

1 reference

27 July 2017

M Crecco

series ordinal

3

1 reference

27 July 2017

F Calabresi

series ordinal

4

1 reference

27 July 2017

1 January 1994

1 reference

Investigational New Drugs

27 July 2017

1 reference

27 July 2017

12

1 reference

27 July 2017

111-119

1 reference

27 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00874440

27 July 2017

0 references

cites work

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Action of 2',2'-difluorodeoxycytidine on DNA synthesis

1 reference

12 December 2020

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

12 December 2020

Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine

1 reference

12 December 2020

Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units

1 reference

12 December 2020

Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

1 reference

12 December 2020

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

The calculation of received dose intensity

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00874440

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference